✓ Medically reviewed by · Last reviewed: May 2026
Pharmacy Researcher · 8 years experience
Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.
Key takeaways
- Both are GHRH analogues binding the same receptor. Different research applications come from structural-stability differences, not mechanism differences.
- Tesamorelin has FDA-approved comparator drug status (Egrifta, for HIV-associated lipodystrophy). Sermorelin has no FDA-approved comparator.
- Sermorelin is the prototype 1-29 GHRH fragment, used historically as a reference compound. Tesamorelin is the long-acting modified analogue developed for clinical use.
- Tesamorelin has documented -15.2% visceral fat reduction at 26 weeks in the LIPO-2 trial (HIV-LD population). Sermorelin has limited modern clinical-trial data.
- This guide compares the two on structure, clinical data, and research applicability.
Tesamorelin vs Sermorelin: The FDA-Approved GHRH Analogue vs the Prototype 1-29 Fragment
Both molecules are GHRH analogues. Both bind the same pituitary GHRH receptor. Both produce GH release through fundamentally the same mechanism. The differences live in the structural modifications — tesamorelin’s N-terminal trans-3-hexenoyl modification supports daily-dose protocols with stable plasma exposure and clinical-trial-grade data; sermorelin’s unmodified 1-29 fragment is the prototype reference compound with very short half-life. This guide covers when to pick each.
Quick verdict
- Need clinical-trial-grade data: Tesamorelin. Egrifta is FDA-approved; LIPO-1 / LIPO-2 trial data is published.
- Visceral-fat-specific research: Tesamorelin. The only GHRH analogue with documented visceral-fat readouts.
- Baseline / reference GHRH compound: Sermorelin. The prototype 1-29 fragment.
- Cost-effective GHRH research: Sermorelin (lower per-mg pricing reflects historical-prototype status).
Mechanism: identical receptor, different stability
Sermorelin (CAS 86168-78-7) is the 29-amino-acid N-terminal fragment of native GHRH. Native GHRH is 44 amino acids; sermorelin retains 100% of the receptor-binding activity in the first 29 residues. It is the molecule that established the principle that GHRH activity can be reduced to a peptide-synthesizable short sequence. Half-life is short (~10-15 minutes, similar to native GHRH), reflecting rapid enzymatic cleavage by aminopeptidases.
Tesamorelin (CAS 218949-48-5) is sermorelin’s structurally modified clinical-development form. The molecule carries an N-terminal trans-3-hexenoyl group that confers enzymatic stability without changing the GHRH-receptor binding profile. The modification supports daily-dose protocols with relatively stable plasma levels. Tesamorelin is the only GHRH analogue with FDA approval (under the trade name Egrifta, for HIV-associated lipodystrophy, approved 2010 by FDA).
Mechanistically, both produce GH release through pulsatile GHRH-receptor activation on pituitary somatotrophs. The downstream pharmacology is fundamentally the same. The difference is in research-protocol applicability: tesamorelin’s pharmacokinetic profile supports daily-dose protocols with clinical-trial-grade endpoint measurement; sermorelin’s short half-life makes it appropriate for pulse-research protocols and as a baseline reference compound.
Clinical trial data
Tesamorelin’s clinical data is substantive. The LIPO-2 Phase 3 trial in HIV-associated lipodystrophy showed mean visceral adipose tissue reduction of -15.2% at 26 weeks, measured by CT-imaging endpoint. The drug is approved at 2 mg daily SC for this indication. Beyond HIV-LD, tesamorelin has been studied in non-HIV abdominal obesity research, NAFLD / NASH protocols, and adult GH-deficiency research scenarios with published positive readouts.
Sermorelin’s clinical data is older and less robust. The molecule was originally evaluated in paediatric GH-deficiency in the 1990s under the trade name Geref (since discontinued). Modern clinical-trial-grade data in adult populations is limited — sermorelin’s research role has shifted toward serving as a baseline-comparator GHRH compound rather than a primary clinical-development candidate.
Comparison table
| Property | Tesamorelin | Sermorelin |
|---|---|---|
| Receptor | GHRH-R | GHRH-R |
| CAS | 218949-48-5 | 86168-78-7 |
| MW | 5135.8 | 3358.0 |
| N-terminal modification | Trans-3-hexenoyl (stability) | None (native fragment) |
| Half-life | ~30 min (with stable daily-dose plasma levels) | ~10-15 min |
| FDA-approved comparator | Egrifta (HIV-associated lipodystrophy) | None (Geref discontinued) |
| Clinical-trial weight-loss data | -15.2% VAT at 26 wk (LIPO-2) | No modern Phase 3 obesity data |
| Typical research dose | 2 mg daily SC | 100-300 mcg per administration |
| Research role | Visceral fat / clinical-grade GHRH | Baseline / reference compound |
Which to pick (research-protocol logic)
- Visceral-fat-specific research: Tesamorelin. The only GHRH analogue with documented visceral-fat reduction readouts.
- Clinical-precedent research: Tesamorelin (Egrifta is the regulatory-precedent product).
- NAFLD / NASH research: Tesamorelin. Visceral-fat-reduction mechanism extends to hepatic-fat endpoints in published research.
- Baseline GHRH-pulse research: Sermorelin. The prototype compound; ideal as the comparator reference.
- Cost-effective pure-GHRH research: Sermorelin (lower per-mg pricing).
- Synergistic stack with Ipamorelin: Either works mechanically; sermorelin’s short half-life mirrors CJC-1295 without DAC for pulse-preservation, making it an alternative in the classical synergy stack.
Safety and regulatory status
Tesamorelin’s comparator drug Egrifta is FDA-approved for HIV-associated lipodystrophy specifically — this is the only approved indication. The research-grade lyophilized peptide on the catalogue is not the finished pharmaceutical product. Sermorelin has no current FDA-approved comparator drug. Both compounds are sold for in-vitro laboratory research and analytical reference use only. Class-level safety considerations include fluid retention and arthralgia, transient injection-site reactions, and theoretical concerns around sustained GH/IGF-1 elevation. None of this is medical advice.
FAQ
Is tesamorelin “just sermorelin with a stability modification”?
Essentially yes — mechanistically. The two molecules share the same GHRH-receptor binding profile and produce GH release through the same pathway. Tesamorelin’s structural difference (the N-terminal trans-3-hexenoyl modification) is a stability engineering — it extends the time the molecule remains active in plasma without changing the underlying pharmacology. The clinical-trial-grade data on tesamorelin reflects the pharmacokinetic improvement enabling daily-dose protocols, not a fundamentally different mechanism.
Why does only tesamorelin have FDA approval?
Theratechnologies developed tesamorelin specifically for the HIV-associated lipodystrophy indication, ran the Phase 3 LIPO-1 and LIPO-2 trials, and obtained FDA approval in 2010 (under the trade name Egrifta). Sermorelin was originally evaluated in paediatric GH-deficiency in the 1990s (under the trade name Geref) but the manufacturer (EMD Serono) discontinued the product in 2008 for commercial rather than safety reasons.
Can sermorelin be used for visceral-fat research?
Mechanically yes — sermorelin produces GH release via the same receptor that tesamorelin acts on, and GH-mediated lipolysis includes visceral-fat selectivity. But the documented visceral-fat readouts in clinical trials are tesamorelin-specific; sermorelin would be the experimental arm against tesamorelin as the comparator reference rather than a substitute for tesamorelin in a visceral-fat-specific research design.
Are the dose levels comparable across the two?
Different. Tesamorelin: 2 mg daily SC (the FDA-approved dose). Sermorelin: typically 100-300 mcg per administration, sometimes thrice daily. The dose difference reflects the molecular-weight difference (tesamorelin is the larger molecule) and the pharmacokinetic profile difference. Direct “milligram equivalence” comparison is not meaningful.
Which is the better synergistic-stack partner for Ipamorelin?
The classical synergy stack uses CJC-1295 without DAC as the GHRH arm. Sermorelin’s short half-life mirrors CJC-1295 without DAC’s pharmacokinetics and is a valid alternative for the GHRH arm. Tesamorelin’s longer plasma residence makes the stack less clean from a pulse-pharmacology standpoint — the synergy logic depends on tight temporal co-administration of both arms.
How does tesamorelin compare to retatrutide / tirzepatide for visceral fat?
Different mechanisms. Tesamorelin’s visceral-fat reduction is GH-axis-mediated (pulsatile GHRH-receptor activation produces visceral-selective lipolysis). Retatrutide and tirzepatide produce broader fat reduction (all fat depots, not just visceral) through appetite suppression and direct hepatic energy expenditure. For visceral-fat-specific research, tesamorelin is the more targeted molecule.
Storage protocol?
Lyophilized vials at -20 °C long-term or 2-8 °C as working stock; reconstituted with bacteriostatic water; reconstituted solution at 2-8 °C with use within ~30 days; protect from light; never freeze-thaw.
Bottom line
Tesamorelin and sermorelin are mechanistically the same GHRH-receptor agonist with different structural-stability profiles. Tesamorelin is the FDA-approved-comparator clinical-development molecule, ideal for visceral-fat-specific research and clinical-precedent protocol design. Sermorelin is the prototype 1-29 GHRH fragment, ideal as the baseline / reference compound and as the cost-effective GHRH option for pulse-research protocols. Both have valid research-protocol roles. See Best GH peptides for full cluster context.
Related research guides
Written by
Sophie ChenPharmaceutical Content Researcher · 8 years experience
Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.